Norfloxacin: Difference between revisions
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''Norfloxacin''' is a synthetic [[chemotherapeutic]] [[antibacterial]] agent<ref>{{Cite journal | last1 = Nelson | first1 = JM. | last2 = Chiller | first2 = TM. | last3 = Powers | first3 = JH. | last4 = Angulo | first4 = FJ. | title = Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. | journal = Clin Infect Dis | volume = 44 | issue = 7 | pages = 977–80 | month = Apr | year = 2007 | doi = 10.1086/512369 | pmid = 17342653 }}</ref><ref>{{Cite journal | last1 = Padeĭskaia | first1 = EN. | title = [Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections] | journal = Antibiot Khimioter | volume = 48 | issue = 9 | pages = 28–36 | year = 2003 | pmid = 15002177 }}</ref> occasionally used to treat common as well as complicated [[urinary tract infections]].<ref>{{Cite journal | last1 = Rafalsky | first1 = V. | last2 = Andreeva | first2 = I. | last3 = Rjabkova | first3 = E. | title = Quinolones for uncomplicated acute cystitis in women | journal = Cochrane Database Syst Rev | volume = 3 | pages = CD003597 | year = 2006 | doi = 10.1002/14651858.CD003597.pub2 | pmid = 16856014 | last4 = Rafalsky | first4 = Vladimir V | editor1-last = Rafalsky | editor1-first = Vladimir V }}</ref> It is sold under various brand names with the most common being '''Noroxin'''. In form of [[Eye drop|ophthalmic]] solutions it is known as '''Chibroxin''' (Apiflox eye drops in Jordan <ref>http://www.jfda.jo/</ref>). Norfloxacin is a first generation synthetic [[fluoroquinolone]] (quinolone) developed by Kyorin Seiyaku K.K. (Kyorin).<ref>{{cite web |url=http://www.faqs.org/rulings/rulings1999HQ545710.html |title=HQ 545710 |publisher=faqs.org |date=30 October 1998 }}</ref> | |||
==Category== | ==Category== | ||
Revision as of 21:55, 8 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Norfloxacin is a synthetic chemotherapeutic antibacterial agent[1][2] occasionally used to treat common as well as complicated urinary tract infections.[3] It is sold under various brand names with the most common being Noroxin. In form of ophthalmic solutions it is known as Chibroxin (Apiflox eye drops in Jordan [4]). Norfloxacin is a first generation synthetic fluoroquinolone (quinolone) developed by Kyorin Seiyaku K.K. (Kyorin).[5]
Category
Fluoroquinolone
US Brand Names
NOROXIN®,CHIBROXIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Norfloxacin inhibits bacterial deoxyribonucleic acid synthesis and is bactericidal. At the molecular level, three specific events are attributed to norfloxacin in E. coli cells:
inhibition of the ATP-dependent DNA supercoiling reaction catalyzed by DNA gyrase, inhibition of the relaxation of supercoiled DNA, promotion of double-stranded DNA breakage.
References
- ↑ Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. (2007). "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story". Clin Infect Dis. 44 (7): 977–80. doi:10.1086/512369. PMID 17342653. Unknown parameter
|month=ignored (help) - ↑ Padeĭskaia, EN. (2003). "[Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections]". Antibiot Khimioter. 48 (9): 28–36. PMID 15002177.
- ↑ Rafalsky, V.; Andreeva, I.; Rjabkova, E.; Rafalsky, Vladimir V (2006). Rafalsky, Vladimir V, ed. "Quinolones for uncomplicated acute cystitis in women". Cochrane Database Syst Rev. 3: CD003597. doi:10.1002/14651858.CD003597.pub2. PMID 16856014.
- ↑ http://www.jfda.jo/
- ↑ "HQ 545710". faqs.org. 30 October 1998.